BIO Elects New Board Members and Officers for the 2014-2015 TermJun 23 2014
San Diego, Calif. (June 23, 2014 5:00 PM PST)— The Biotechnology Industry Organization (BIO) is pleased to announce the re-election of Rachel King, President & CEO, GlycoMimetics, Inc., as the Chair of its Board of Directors for the 2014-2015 term, the election of Dan Junius, President & CEO, ImmunoGen, as its new Board Treasurer, and the re-election of David Pyott, Chairman, President & CEO, Allergan, Inc., as Board Secretary. The Board also elected 19 of its Directors to serve on BIO’s Board Executive Committee for the new term. In addition, BIO welcomes the election of 10 new members to its Board of Directors, voted upon at this year’s 2014 BIO International Convention.
|
|
BIO Elects New Board Members and Officers for the 2014-2015 TermJun 23 2014
San Diego, Calif. (June 23, 2014 5:00 PM PST)— The Biotechnology Industry Organization (BIO) is pleased to announce the re-election of Rachel King, President & CEO, GlycoMimetics, Inc., as the Chair of its Board of Directors for the 2014-2015 term, the election of Dan Junius, President & CEO, ImmunoGen, as its new Board Treasurer, and the re-election of David Pyott, Chairman, President & CEO, Allergan, Inc., as Board Secretary. The Board also elected 19 of its Directors to serve on BIO’s Board Executive Committee for the new term. In addition, BIO welcomes the election of 10 new members to its Board of Directors, voted upon at this year’s 2014 BIO International Convention.
|
|
Indiana Governor Mike Pence to be Presented 2014 BIO Governor of the Year AwardJun 20 2014
BIO announced today that Indiana Governor Mike Pence was honored with its 2014 Governor of the Year award in recognition of his leadership and commitment to strengthening the biotechnology and health sectors within Indiana.
|
|
BIO Issues Call for Papers for 2014 Pacific Rim Summit on Industrial Biotechnology and BioenergyJun 13 2014
The Biotechnology Industry Organization (BIO) invites leaders from the biotechnology, chemical and agricultural industries to submit proposals and abstracts for panels, individual papers and poster presentations for the 2014 Pacific Rim Summit on Industrial Biotechnology and Bioenergy. This unique conference will be held December 7-9, 2014 in San Diego at the Westin Gaslamp Quarter.
|
|
Interactive Science Communication Sessions at 2014 BIO Livestock Biotech SummitJun 3 2014
Attendees will get the opportunity to hone their communications techniques during specially produced communications programming at this year’s Livestock Biotech Summit. The 2014 Summit will be held September 16-18, 2014, in Sioux Falls, South Dakota at the Sioux Falls Convention Center.
|
|
EPA Should Recognize Roles of Biomass, Biotechnology in Mitigating Global Warming, BIO SaysJun 2 2014
The Obama administration's Carbon Pollution Emission Guidelines for Existing Stationary Sources: Electric Utility Generating Units missed an opportunity to give industry clear guidance that using sustainable biomass mitigates greenhouse gas emissions by recycling atmospheric carbon.
|
|
New Study Raises Concerns About Hospital Acquisitions of Physician-Based Oncology Practices within the 340B Drug Discount ProgramMay 29 2014
Many participating hospitals appear to be deviating from the program’s original intent by leveraging 340B discounts for financial gain, rather than improving patient access
|
|
Delaware Governor Signs Bill Granting Patient Access to BiosimilarsMay 29 2014
Delaware Governor Markell signed legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
|
|
BIO Statement on Removal of Patent Legislation from Judiciary Committee AgendaMay 21 2014
BIO applauds Chairman Leahy’s decision to remove the controversial patent bill from the Senate Judiciary Committee’s agenda until greater stakeholder consensus can be achieved.
|
|
BIO Urges Governor Markell to Sign Bill That Ensures Patient Access to Interchangeable Biologic MedicinesMay 16 2014
BIO and Delaware Bio call upon Governor Markell to sign critical legislation to create a pathway for the substitution of interchangeable biologic medicines.
|
